Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

7 October 2016

AstraZeneca ink pact with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US

AstraZeneca announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.
- Read more about Amgen present data from Imlygic with Vectibix at ESMO 2016 congress
Amgen announced that new data on Imlygic (talimogene laherparepvec) in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix (panitumumab) will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, October 7-11, 2016, in Copenhagen.
- Read more about Eisai’s Belviq XR® - a new once-daily formulation now available in the united states
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR® 20mg tablets, a new once-daily formulation of BELVIQ® (generic name: lorcaserin hydrochloride) for chronic weight management in the United States.
BELVIQ XR is an extended release formulation proven to be slowly absorbed in the body and to last throughout the day. The availability of once-daily BELVIQ XR (20mg) in a single tablet provides patients with another dosing option in addition to the conventional twice-daily BELVIQ (10mg).
- Read more about Lilly's subsidiary Elanco purchase Boehringer Ingelheim's veterinary vaccine portfolio
Elanco US, Inc., a subsidiary of Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s (BIVI) US feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site – for $885 million, including the estimated cost of acquired inventory. The deal will diversify Elanco's US companion animal portfolio by complementing its offerings for dogs and cats.

[adsense:336x280:8701650588]
- Read more about Elixirgen launch new Quick-Tissue kits to revolutionize skeletal muscle & neuron differentiation
Elixirgen, LLC, a Baltimore-based biotechnology company, launched Quick-Muscle 1.0, a groundbreaking biological reagent that develops skeletal muscle cells from human stem cells in just a few days — a cutting-edge advancement for a laboratory process that previously took a month or longer.
- Read more about Eisai Launch Uritos® Tablets For Overactive Bladder In Thailand
Eisai Co., Ltd. and KYORIN Holdings, Inc. announced that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos® Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand.
- Read more about Janssen present New Phase 3 Data In Treatment of Moderate to Severe Plaque Psoriasis
Janssen Research & Development, LLC (Janssen) announced findings from the first of three pivotal Phase 3 studies evaluating guselkumab, a subcutaneously administered anti-interleukin (IL)-23 monoclonal antibody in late-stage development for the treatment of adults with moderate to severe plaque psoriasis.
- Read more about European Commission grant transfer of Alprolix® marketing authorisation to Sobi™
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Alprolix® (eftrenonacog alfa), a recombinant clotting factor therapy developed for the treatment of haemophilia B, from Biogen[i] to Sobi, making Sobi the marketing authorisation holder (MAH) in the EU.
- Read more about Aralez Pharma acquire rights to Toprol-XL tablets in US from AstraZeneca
AstraZeneca has entered into an agreement with Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez Pharmaceuticals Inc., for the rights to branded and authorised generic Toprol-XL (metoprolol succinate) in the US. Toprol-XL is a beta-blocker medicine for the control of hypertension (high blood pressure), angina (chest pain) and heart failure. It was first approved in the US in 1992.
- Read more about Yoshinori Ohsumi : Nobel Prize Winner for Medicine
This year's Nobel Laureate discovered and elucidated mechanisms underlying autophagy, a fundamental process for degrading and recycling cellular components.

The word autophagy originates from the Greek words auto-, meaning "self", and phagein, meaning "to eat". Thus,autophagy denotes "self eating". This concept emerged during the 1960's, when researchers first observed that the cell could destroy its own contents by enclosing it in membranes, forming sack-like vesicles that were transported to a recycling compartment, called the lysosome, for degradation. Difficulties in studying the phenomenon meant that little was known until, in a series of brilliant experiments in the early 1990's, Yoshinori Ohsumi used baker's yeast to identify genes essential for autophagy. He then went on to elucidate the underlying mechanisms for autophagy in yeast and showed that similar sophisticated machinery is used in our cells.